ReviewBest practice & research. Clinical endocrinology & metabolism2011
The GH/IGF-1 system in critical illness.
Review in Best practice & research. Clinical endocrinology & metabolism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 84 citations in OpenAlex.
- Effects of gabapentin on slow-wave sleep period in critically ill adult patients: A randomized controlled trial.Clinical and translational science · 2024Trial
- Measured resting energy expenditure via indirect calorimetry of critically ill patients: A comparison with predictive equations.Asia Pacific journal of clinical nutrition · 2026Article
- Growth Hormone-Insulin-like Growth Factor Axis and GDF-15 in Critical Illness: Implications for Survival Stratification.Life (Basel, Switzerland) · 2026Article
- Addressing metabolic demands during veno-venous extracorporeal life support: A narrative review.JPEN. Journal of parenteral and enteral nutrition · 2026Review
- Endocrine disruptions in thermal injuries: exploring immune system interactions.Physiological reviews · 2026Review
- Patients Having Major Abdominal Cancer Surgery Exhibit Significant Acute Muscle Wasting.Journal of cachexia, sarcopenia and muscle · 2025Article
- IGFBP-2 in Critical Illness: A Prognostic Marker in the Growth Hormone/Insulin-like Growth Factor Axis.Pathophysiology : the official journal of the International Society for Pathophysiology · 2024Review
- Navigating sarcopenia in COVID-19 patients and survivors: Understanding the long-term consequences, transitioning from hospital to community with mechanisms and interventions for future preparedness.Aging medicine (Milton (N.S.W)) · 2024Review
- Serum Insulin-like Growth Factor-Binding Protein-2 as a Prognostic Factor for COVID-19 Severity.Biomedicines · 2024Article
- Plasma Insulin-like Growth Factor-Binding Protein-2 of Critically Ill Patients Is Related to Disease Severity and Survival.Biomedicines · 2023Article
- [Genetics in sports-muscle injuries].Orthopadie (Heidelberg, Germany) · 2023Review
- Growth hormone level in COVID-19 patients.Northern clinics of Istanbul · 2022Article
- Article
- The Biochemical Diagnosis of Acromegaly.Journal of clinical medicine · 2021Review
- Insulin-Like Growth Factor-1: A Promising Therapeutic Target for Peripheral Nerve Injury.Frontiers in bioengineering and biotechnology · 2021Review
- Hypothesis: Mechanisms That Prevent Recovery in Prolonged ICU Patients Also Underlie Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).Frontiers in medicine · 2021Article
- Theory: Treatments for Prolonged ICU Patients May Provide New Therapeutic Avenues for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).Frontiers in medicine · 2021Article
- Covid-19 and Growth Hormone/Insulin-Like Growth Factor 1: Study in Critically and Non-Critically Ill Patients.Frontiers in endocrinology · 2021Article
- Growth hormone as a rescue treatment in maple syrup urine disease with lessons from pediatric burn literature, case report and brief literature review.Molecular genetics and metabolism reports · 2020Article
- Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The Growth Hormone and Insulin-like Growth Factor-1 (IGF-1) axis plays a pivotal role in critical illness, with a derangement leading to profound changes in metabolism. Protein wasting with skeletal muscle loss, delayed wound healing, and impaired recovery of organ systems are some of the most feared consequences. The use of human recombinant Growth Hormone (rhGH) and Insulin-like Growth Factor-1 (IGF-1) - alone and in combination - has been studied extensively in preclinical and clinical trials. This article reviews the current knowlegde and clinical practice of the use of rhGh and IGF-1 in critically ill patients, with a special focus on the trauma and burns patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.